Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Heike Seifert

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
BMJ Case Reports|July 13, 2013
Not your usual diarrhoea: severe colonic toxicity of mycophenolate due to intestinal CMV and EBV infectionHeike Seifert, Christoph Hess, Luici Terracciano, et al.
Pigment Cell & Melanoma Research|September 29, 2015
Extrinsic factors can mediate resistance to BRAF inhibition in central nervous system melanoma metastasesHeike Seifert, Eishu Hirata, Martin Gore, et al.
Melanoma Research|December 20, 2015
Prognostic markers and tumour growth kinetics in melanoma patients progressing on vemurafenibHeike Seifert, Rosalie Fisher, Juan Martin-Liberal, et al.
Gynecologic Oncology|August 31, 2015
Poor performance status (PS) is an indication for an aggressive approach to neoadjuvant chemotherapy in patients with advanced epithelial ovarian cancer (EOC)Heike Seifert, Alexandros Georgiou, Helen Alexander, et al.
BMC Cancer|January 13, 2018
Adjuvant treatment of resectable biliary tract cancer with cisplatin plus gemcitabine: A prospective single center phase II studyAlexander R Siebenhüner, Heike Seifert, Helga Bachmann, et al.
Cancer Cell|January 21, 2015
Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addictionGatien Moriceau, Willy Hugo, Aayoung Hong, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
BMJ Case Reports|July 13, 2013
Not your usual diarrhoea: severe colonic toxicity of mycophenolate due to intestinal CMV and EBV infectionHeike Seifert, Christoph Hess, Luici Terracciano, et al.
Pigment Cell & Melanoma Research|September 29, 2015
Extrinsic factors can mediate resistance to BRAF inhibition in central nervous system melanoma metastasesHeike Seifert, Eishu Hirata, Martin Gore, et al.
Melanoma Research|December 20, 2015
Prognostic markers and tumour growth kinetics in melanoma patients progressing on vemurafenibHeike Seifert, Rosalie Fisher, Juan Martin-Liberal, et al.
Gynecologic Oncology|August 31, 2015
Poor performance status (PS) is an indication for an aggressive approach to neoadjuvant chemotherapy in patients with advanced epithelial ovarian cancer (EOC)Heike Seifert, Alexandros Georgiou, Helen Alexander, et al.
BMC Cancer|January 13, 2018
Adjuvant treatment of resectable biliary tract cancer with cisplatin plus gemcitabine: A prospective single center phase II studyAlexander R Siebenhüner, Heike Seifert, Helga Bachmann, et al.
Cancer Cell|January 21, 2015
Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addictionGatien Moriceau, Willy Hugo, Aayoung Hong, et al.
Pageof 1